Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the five ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $18.00.

Several research analysts have recently issued reports on ENTA shares. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. JMP Securities upped their price objective on Enanta Pharmaceuticals from $23.00 to $24.00 and gave the company a "market outperform" rating in a research note on Tuesday. Finally, Wall Street Zen raised Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday, February 19th.

Institutional Trading of Enanta Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC boosted its holdings in Enanta Pharmaceuticals by 46.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock valued at $41,000 after acquiring an additional 2,274 shares during the last quarter. American Century Companies Inc. boosted its holdings in Enanta Pharmaceuticals by 8.2% in the first quarter. American Century Companies Inc. now owns 40,004 shares of the biotechnology company's stock valued at $221,000 after acquiring an additional 3,042 shares during the last quarter. AlphaQuest LLC boosted its holdings in Enanta Pharmaceuticals by 16.4% in the fourth quarter. AlphaQuest LLC now owns 22,260 shares of the biotechnology company's stock valued at $128,000 after acquiring an additional 3,137 shares during the last quarter. Invesco Ltd. boosted its holdings in Enanta Pharmaceuticals by 7.3% in the fourth quarter. Invesco Ltd. now owns 46,614 shares of the biotechnology company's stock valued at $268,000 after acquiring an additional 3,186 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in Enanta Pharmaceuticals in the fourth quarter valued at approximately $26,000. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Trading Up 3.6%

Enanta Pharmaceuticals stock traded up $0.26 during midday trading on Tuesday, reaching $7.47. The company's stock had a trading volume of 118,893 shares, compared to its average volume of 285,504. Enanta Pharmaceuticals has a 52 week low of $4.09 and a 52 week high of $17.24. The business has a 50-day moving average price of $5.53 and a 200-day moving average price of $6.20. The stock has a market cap of $159.69 million, a PE ratio of -1.51 and a beta of 0.81.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.04) by ($0.02). Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. The business had revenue of $14.93 million during the quarter, compared to the consensus estimate of $15.96 million. As a group, research analysts predict that Enanta Pharmaceuticals will post -4.65 EPS for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.